Endometrial hyperplastic processes: etiopathogenesis, risk factors, polymorphism of candidate genes

Ponomarenko I.V., Polonikov A.V., Churnosov M.I.

1 Belgorod State National Research University, Belgorod, Russia 2 Kursk State Medical University, Ministry of Health of Russia, Kursk, Russia
Objective. To carry out a systems analysis of the data available in the current literature on the etiopathogenesis, risk factors, and genetic determinants of endometrial hyperplastic processes.
Materials and methods. The review includes the updates of foreign and Russian articles found in Pubmed on this topic.
Results. The paper presents the basic etiopathogenetic mechanisms of endometrial hyperplasia, their risk factors, and genetic determinants.
Conclusion. According to modern concepts, endometrial hyperplastic processes are a multifactorial disease, the development of which involves the processes of hormone-dependent and hormone-independent endometrial cell proliferation, chronic inflammation, as well as genetic and epigenetic mechanisms.

Keywords

endometrial hyperplasia
etiology
pathogenesis
risk factors
polymorphism of candidate genes

References

  1. Киселев В.И., Сидорова И.С., Унанян А.Л., Муйжнек Е.Л. Гиперпластические процессы органов женской репродуктивной системы: теория и практика. М.: МЕДПРАКТИКА-М; 2010. 468с.
  2. Адамян Л.В., ред. Cочетанные доброкачественные опухоли и гиперпластические процессы матки (миома, аденомиоз, гиперплазия эндометрия). Проект клинических рекомендаций по ведению больных. М.: Научный центр акушерства, гинекологии и перинатологии им. В.И. Кулакова Минздрава России; 2015. 92с.
  3. Chandra V., Kim J.J., Benbrook D.M., Dwivedi A., Rai R. Therapeutic options for management of endometrial hyperplasia. J. Gynecol. Oncol. 2016; 27(1): e8. https://dx.doi.org/10.3802/jgo.2016.27.e8.
  4. Kadirogullari P., Atalay C.R., Ozdemir O., Sari E.M. Prevalence of co-existing endometrial carcinoma in patients with preoperative diagnosis of endometrial hyperplasia. J. Clin. Diagn. Res. 2015; 9(10): QC10-4.
  5. Ørbo A., Arnes M., Vereide A., Straume B. Relapse risk of endometrial hyperplasia after treatment with the levonorgestrel‐impregnated intrauterine system or oral progestogens. BJOG. 2016; 123(9): 1512-9. https://dx.doi.org/10.1111/1471-0528.13763.
  6. Erdem B., Aşıcıoğlu O., Seyhan N.A., Peker N., Ülker V., Akbayır Ö. Can concurrent high-risk endometrial carcinoma occur with atypical endometrial hyperplasia? Int. J. Surg. 2018; 53: 350-3. https://dx.doi.org/10.1016/j.ijsu.2018.04.019.
  7. Iversen M.L., Dueholm M. Complex non atypical hyperplasia and the subsequent risk of carcinoma, atypia and hysterectomy during the following 9-14 years. Eur. J. Obstet. Gynecol. Reprod. Biol. 2018; 222: 171-5. https://dx.doi.org/10.1016/j.ejogrb.2018.01.026.
  8. Чернуха Г.Е., Асатурова А.В., Иванов И.А., Думановская М.Р. Структура патологии эндометрия в различные возрастные периоды. Акушерство и гинекология. 2018; 8: 129-34.
  9. Plaza-Parrochia F., Romero C., Valladares L., Vega M. Endometrium and steroids, a pathologic overview. Steroids. 2017; 126: 85-91. https://dx.doi.org/10.1016/j.steroids.2017.08.007.
  10. Yoo J.Y., Kang H.B., Broaddus R.R., Risinger J.I., Choi K.C., Kim T.H. MIG-6 suppresses endometrial epithelial cell proliferation by inhibiting phospho-AKT. BMC Cancer. 2018; 18: 605. https://dx.doi.org/10.1186/s12885-018-4502-7.
  11. Шрамко С.В., Гуляева Л.Ф., Баженова Л.Г., Левченко В.Г. Миома матки и аденомиоз: молекулярная характеристика по экспрессии генов стероидных рецепторов. Акушерство и гинекология. 2018; 4: 58-63.
  12. Кузнецова И.В. Гиперпластические процессы эндометрия. М.; 2009. 48с.
  13. Banas T., Pitynski K., Mikos M., Cielecka-Kuszyk J. Endometrial polyps and benign endometrial hyperplasia present increased prevalence of DNA fragmentation factors 40 and 45 (DFF40 and DFF45) together with the antiapoptotic B-cell lymphoma (Bcl-2) protein compared with normal human endometria. Int. J. Gynecol. Pathol. 2018; 37(5): 431-40.https://dx.doi.org/10.1097/PGP.0000000000000442.
  14. Trabzonlu L., Muezzinoglu B., Corakci A. BCL-2 and PAX2 expressions in EIN which had been previously diagnosed as non-atypical hyperplasia. Pathol. Oncol. Res. 2017; Dec 21. https://dx.doi.org/10.1007/s12253-017-0378-0.
  15. Kaushal J.B., Sankhwar P., Kumari S., Popli P., Shukla V., Hussain M.K. et al. The regulation of Hh/Gli1 signaling cascade involves Gsk3β- mediated mechanism in estrogen-derived endometrial hyperplasia. Sci. Rep. 2017; 7(1): 6557. https://dx.doi.org/10.1038/s41598-017-06370-1.
  16. Farah O., Biechele S., Rossant J., Dufort D. Porcupine-dependent Wnt signaling controls stromal proliferation and endometrial gland maintenance through the action of distinct WNTs. Dev. Biol. 2017; 422(1): 58-69. https://dx.doi.org/10.1016/j.ydbio.2016.11.023.
  17. Farah O., Biechele S., Rossant J., Dufort D. Regulation of porcupine-dependent Wnt signaling is essential for uterine development and function. Reproduction. 2018; 155(1): 93-102. https://dx.doi.org/10.1530/REP-17-0436.
  18. Song D., Feng X., Zhang Q., Xia E., Xiao Y., Xie W. et al. Prevalence and confounders of chronic endometritis in premenopausal women with abnormal bleeding or reproductive failure. Reprod. Biomed. Online. 2018; 36(1): 78-83. https://dx.doi.org/10.1016/j.rbmo.2017.09.008.
  19. Sanderson P.A., Critchley H.O.D., Williams A.R.W., Arends M.J., Saunders P.T.K. New concepts for an old problem: the diagnosis of endometrial hyperplasia. Hum. Reprod. Update. 2017; 23(2): 232-54. https://dx.doi.org/10.1093/humupd/dmw042.
  20. Suidan R.S., He W., Sun C.C., Zhao H., Fleming N.D., Ramirez P. et al. Impact of body mass index and operative approach on surgical morbidity and costs in women with endometrial carcinoma and hyperplasia. Gynecol. Oncol. 2017; 145(1): 55-60. https://dx.doi.org/10.1016/j.ygyno.2017.01.025.
  21. Mitsuhashi A., Uehara T., Hanawa S., Shozu M. Prospective evaluation of abnormal glucose metabolism and insulin resistance in patients with atypical endometrial hyperplasia and endometrial cancer. Support Care Cancer. 2017; 25(5): 1495-501. https://dx.doi.org/10.1007/s00520-016-3554-y.
  22. Wartko P.D., Beck T.L., Reed S.D., Mueller B.A., Hawes S.E. Association of endometrial hyperplasia and cancer with a history of gestational diabetes. Cancer Causes Control. 2017; 28(8): 819-28. https://dx.doi.org/10.1007/s10552-017-0908-9.
  23. Оразов М.Р. Дискуссионные вопросы ведения пациенток с гиперплазией эндометрия. Акушерство и гинекология: новости, мнения, обучение. 2016; 3: 46-58.
  24. Ramezanali F., Khalili G., Arabipoor A., Bagheri Lankarani N., Moini A. Relationships between serum luteinizing hormone level, endometrial thickness and body mass index in polycystic ovary syndrome patients with and without endometrial hyperplasia. Int. J. Fertil. Steril. 2016; 10(1): 36-41.
  25. Zheng X.R., Pan X., Zhang J., Cao X. Hyperinsulinemia-induced PAX6 expression promotes endometrial epithelial cell proliferation via negatively modulating p27 signaling. Biomed. Pharmacother. 2018; 97: 802-8. https://dx.doi.org/10.1016/j.biopha.2017.10.156.
  26. Qi J., Wang W., Zhu Q., He Y., Lu Y., Wang Y. et al. Local cortisol elevation contributes to endometrial insulin resistance in polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2018; 103(7): 2457-67. https://dx.doi.org/10.1210/jc.2017-02459.
  27. Gawron I., Łoboda M., Babczyk D., Ludwin I., Basta P., Pityński K. et al. Endometrial cancer and hyperplasia rate in women before menopause with abnormal uterine bleeding undergoing endometrial sampling. Przegl. Lek. 2017; 74(4): 139-43.
  28. Sahoo S.S., Lombard J.M., Ius Y., O’Sullivan R., Wood L.G., Nahar P. et al. Adipose-derived VEGF-mTOR signaling promotes endometrial hyperplasia and cancer: implications for obese women. Mol. Cancer Res. 2018; 16(2): 309-21. https://dx.doi.org/10.1158/1541-7786.MCR-17-0466.
  29. Фэн И., Сидорова И.С., Станоевич И.В., Унанян А.Л., Кудрина Е.А. Сочетание гиперпластических процессов эндометрия с хроническим эндометритом. Акушерство, гинекология и репродукция. 2012; 6(1): 31-3.
  30. Douglas N.I., Pavlova T.U., Burtseva T.E., Rad Y.G., Petrova P.G., Odland J.Ø. Women’s reproductive health in the Sakha Republic (Yakutia). Int. J. Circumpolar Health. 2014; Oct 30: 73. eCollection 2014. https://dx.doi.org/10.3402/ijch.v73.25872.
  31. Dieudonné A.S., Lambrechts D., Smeets D., Belmans A., Wildiers H., Paridaens R. et al. The rs1800716 variant in CYP2D6 is associated with an increased double endometrial thickness in postmenopausal women on tamoxifen. Ann. Oncol. 2014; 25(1): 90-5. https://dx.doi.org/10.1093/annonc/mdt399.
  32. van der Putten L.J.M., van Hoof R., Tops B.B.J., Snijders M.P.L.M., van den Berg-van Erp S.H., van der Wurff A.A.M. et al. Molecular profiles of benign and (pre)malignant endometrial lesions. Carcinogenesis. 2017; 38(3): 329- 35. https://dx.doi.org/10.1093/carcin/bgx008.
  33. Ордиянц И.М., Аракелов С.Э., Павлова Е.А., Дмитриева Е.В., Куулар А.А. Генетический риск развития гиперпластического процесса в эндометрии и в молочных железах, ассоциированный полиморфизмом генов-кандидатов. Мать и дитя в Кузбассе. 2014; 4: 62-5.
  34. Харенкова Е.Л., Артымук Н.В., Иленко Е.В., Гуляева Л.Ф., Хвостова Е.П. Генетический полиморфизм ферментов метаболизма эстрогенов у женщин с гиперпластическими процессами эндометрия в перименопаузе. Бюллетень Сибирского отделения Российской академии медицинских наук. 2009; 2: 5-8.
  35. Demakova N.A., Altuchova O.B., Orlova V.S., Pachomov S.P., Krikun E.N. Associations of cytokines genetic polymorphisms with development of endometrial hyperplasia. Res. J. Pharm. Biol. Chem. Sci. 2014;5(5): 1041-5.
  36. Демакова Н.А. Молекулярно-генетические характеристики пациенток с гиперплазией и полипами эндометрия. Научный результат. Медицина и фармация. 2018; 4(2):26-39. [Demakova N.A. Molecular and genetic characteristics of patients with hyperplasia and endometric polyps. Research Result. Medicine and Pharmacy. 2018;4(2):26-39. (in Russian)]. https://dx.doi.org/10.18413/2313-8955-2018-4-2-0-4.
  37. Altuchova O.B., Demakova N.A., Koneva O.A., Pachomov S.P., Orlova V.S., Golovchenko O.V. Genetic factors of uterine hyperplastic processes. Res. J. Pharm. Biol. Chem. Sci. 2014; 5(6): 1397-400.
  38. Ivanova T.I., Krikunova L.I., Ryabchenko N.I., Mkrtchyan L.S., Khorokhorina V.A., Salnikova L.E. Association of the apolipoprotein E 2 allele with concurrent occurrence of endometrial hyperplasia and endometrial carcinoma. Oxid. Med. Cell. Longev. 2015; 2015: 593658. https://dx.doi.org/10.1155/2015/593658.
  39. Рудых Н.А., Сиротина С.С. Генетические соотношения русских и украинских популяций Белгородской области. Научный результат. Медицина и фармация. 2015;1(3):72-79. [Rudyh N.A., Sirotina S.S. Genetic interrelations of Russian and Ukrainian populations of Belgorod region]. Research Result. Medicine and Pharmacy. 2015;1(3):72-79. (in Russian)]. https://dx.doi.org/10.18413/2313-8955-2015-1-3-72-79.
  40. Пономаренко И.В. Отбор полиморфных локусов для анализа ассоциаций при генетико-эпидемиологических исследованиях. Научный результат. Медицина и фармация. 2018;4(2):40-54. [Ponomarenko I.V. Selection of polymorphic loci for association analysis in genetic-epidemiological studies. Research Result. Medicine and Pharmacy. 2018;4(2):40-54. (in Russian) https://dx.doi.org/10.18413/2313-8955-2018-4-2-0-5
  41. Радзинский В.Е., Алтухова О.Б. Молекулярно-генетические детерминанты бесплодия при генитальном эндометриозе. Научные результаты биомедицинских исследований. 2018; 4(3):21-30. [Radzinsky V.E., Altuchova O.B. Molecular-genetic determinants of infertility in genital endometryosis. Research Results in Biomedicine. 2018;4(3):21-30. (in Russian)]. https://dx.doi.org/10.18413/2313-8955-2018-4-3-0-3.
  42. Nothnick W.B. Non-coding RNAs in uterine development, function and disease. Adv. Exp. Med. Biol. 2016; 886: 171-89. https://dx.doi.org/10.1007/978-94-017-7417-8_9.
  43. Tang S., Dai Y. RNA sequencing reveals significant miRNAs in atypical endometrial hyperplasia. Eur. J. Obstet. Gynecol. Reprod. Biol. 2018; 225: 129-35. https://dx.doi.org/10.1016/j.ejogrb.2018.03.025.
  44. Wu X., Miao J., Jiang J., Liu F. Analysis of methylation profiling data of hyperplasia and primary and metastatic endometrial cancers. Eur. J. Obstet. Gynecol. Reprod. Biol. 2017; 217: 161-6. https://dx.doi.org/10.1016/j.ejogrb.2017.08.036.

Received 12.03.2018

Accepted 20.04.2018

About the Authors

Ponomarenko, Irina V., MD, associate professor of the Department of Biomedical Disciplines of the Medical Institute, Belgorod State National Research University.
308015, Russia, Belgorod, Pobedy str. 85. Tel.: +74722301383. E-mail: ponomarenko_i@bsu.edu.ru. https://orcid.org/0000-0002-5652-0166
Polonikov, Alexey V., MD, professor, head of the Department of Biology, Medical Genetics and Ecology, Kursk State Medical University, Ministry of Health of Russia.
305041, Russia, Kursk, K. Marx str. 3. Tel.: +74712588147. E-mail: polonikovav@kursksmu.net.
Churnosov Mikhail Ivanovich, MD, professor, head of the Department of Biomedical Disciplines Medical Faculty, Belgorod State National Research University.
308015, Russia, Belgorod, Pobedy str. 85. Tel.: +74722301383. E-mail: churnosov@bsu.edu.ru. http://orcid.org/0000-0003- 1254-6134

For citations: Ponomarenko I.V., Polonikov A.V., Churnosov M.I. Endometrial hyperplastic processes: etiopathogenesis, risk factors, polymorphism of candidate genes. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2019; (1): 13-8. (in Russian)
http://dx.doi.org/10.18565/aig.2019.1.13-18

Similar Articles

By continuing to use our site, you consent to the processing of cookies that ensure the proper functioning of the site.